Federated Hermes’s ProQR Therapeutics PRQR Stock Holding History

Federated Hermes’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-261,400	Closed	-$3.63M	–	2206
2019 Q1	$3.63M	Hold	261,400	–	–	0.01%	869
2018 Q4	$4.13M	Hold	261,400	–	–	0.01%	790
2018 Q3	$5.06M	Buy	+261,400	New	+$2.78M	0.01%	801
2014 Q4	–	Sell	-202,500	Closed	-$3.48M	–	2027
2014 Q3	$3.48M	Buy	+202,500	New	+$3.24M	0.01%	767

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Federated Hermes's PRQR Position: Q2 2019 in Review

Federated Hermes sold out of ProQR Therapeutics (PRQR) in Q2 2019, closing a stake of 261,400 shares — an estimated $3.63M sold.

Federated Hermes first reported a position in PRQR in Q3 2014 and held it in 4 quarters. The position peaked at $5.06M in Q3 2018. 55 funds tracked by Wall St. Rank hold PRQR as of Q2 2019.

Federated Hermes reported no remaining ProQR Therapeutics position as of Q2 2019 after selling out during the quarter.
Federated Hermes sold 261,400 ProQR Therapeutics shares in Q2 2019, an estimated $3.63M.
Federated Hermes first reported a position in ProQR Therapeutics in Q3 2014 and held it in 4 quarters.
Federated Hermes's ProQR Therapeutics position peaked at $5.06M in Q3 2018.
55 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2019.

Based on Federated Hermes's 13F filing for Q2 2019, filed 14 Aug 2019.